| 1 | Phase 1 Study to Assess Safety, Tolerability and Pharmacokin… (10.1093/ofid/ofx163.1390) | Abstract References ORCID License | 163.35 | 42 |
| 2 | First-in-Human Study to Assess Safety, Tolerability and Phar… (10.1093/ofid/ofx163.1370) | Abstract References ORCID License | 155.63 | 35 |
| 3 | Automated Outbreak Detection of Hospital-Associated Infectio… (10.1093/ofid/ofv131.60) | Abstract References ORCID | 152.20 | 106 |
| 4 | Improved Outcomes with Plazomicin (PLZ) Compared with Colist… (10.1093/ofid/ofx163.1383) | Abstract References ORCID License | 136.17 | 22 |
| 5 | 1805Use of Stool Transplant to Clear Fecal Colonization with… (10.1093/ofid/ofu051.177) | Abstract References ORCID License | 134.24 | 21 |
| 6 | Absorption, Distribution, and Excretion of 14C-APX001 after… (10.1093/ofid/ofx163.1209) | Abstract References ORCID License | 130.10 | 19 |
| 7 | Plazomicin Vs. Meropenem for Complicated Urinary Tract Infec… (10.1093/ofid/ofx163.1385) | Abstract References ORCID License | 130.10 | 19 |
| 8 | Clinical Outcomes of Serious Infections due to Carbapenem-Re… (10.1093/ofid/ofx163.1392) | Abstract References ORCID License | 130.10 | 19 |
| 9 | Treatment Options for Carbapenem-Resistant Enterobacteriacea… (10.1093/ofid/ofv050) | ORCID License | 126.19 | 333 |
| 10 | SCY-078 Demonstrates Significant Antifungal Activity in a Mu… (10.1093/ofid/ofx163.1207) | Abstract References ORCID License | 125.53 | 17 |
| 11 | Clinical Response of Cefiderocol Compared with Imipenem/Cila… (10.1093/ofid/ofx163.1399) | Abstract References ORCID License | 125.53 | 17 |
| 12 | 824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Foc… (10.1093/ofid/ofu052.532) | Abstract References ORCID License | 123.04 | 16 |
| 13 | 363. National Burden of Candidemia, United States, 2017 (10.1093/ofid/ofy210.374) | Abstract References ORCID | 119.33 | 38 |
| 14 | Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inh… (10.1093/ofid/ofv130.02) | Abstract References ORCID | 118.48 | 37 |
| 15 | A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem… (10.1093/ofid/ofx163.1369) | Abstract References ORCID License | 117.61 | 14 |
| 16 | Sensitivity and Specificity of Duke Criteria for Diagnosis o… (10.1093/ofid/ofx163.1431) | Abstract References ORCID License | 117.61 | 14 |
| 17 | Lactose vs Non-Lactose Fermenting E. coli: Epidemiology, Cli… (10.1093/ofid/ofx163.1546) | Abstract References ORCID License | 117.61 | 14 |
| 18 | Increases in Condomless Sex in the Swiss HIV Cohort Study (10.1093/ofid/ofv077) | Abstract ORCID License | 116.72 | 35 |
| 19 | Intravenous Fosfomycin (ZTI-01) for the Treatment of Complic… (10.1093/ofid/ofx163.1375) | Abstract References ORCID License | 114.61 | 13 |
| 20 | Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-R… (10.1093/ofid/ofx163.631) | Abstract References ORCID License | 114.61 | 13 |
| 21 | A Phase 3 Randomized, Double-blind, Multi-center Study to Co… (10.1093/ofid/ofx163.1413) | Abstract References ORCID License | 107.92 | 11 |
| 22 | 2039. New York State 2016–2018: Progression from <i>Candida… (10.1093/ofid/ofy210.1695) | Abstract References ORCID | 106.12 | 25 |
| 23 | Donor Efficacy in Fecal Microbiota Transplantation for Recur… (10.1093/ofid/ofw194.48) | Abstract References ORCID | 104.85 | 24 |
| 24 | APX001A Protects Immunosuppressed Mice from Rhizopus delemar… (10.1093/ofid/ofx163.1217) | Abstract References ORCID License | 104.14 | 10 |
| 25 | High-volume Sputum Culture for the Diagnosis of Pulmonary As… (10.1093/ofid/ofx163.1598) | Abstract References ORCID License | 104.14 | 10 |
| 26 | Six-Year Surveillance of Diphtheria Outbreak in Indonesia (10.1093/ofid/ofx163.522) | Abstract References ORCID License | 104.14 | 10 |
| 27 | Human Colonization With Multidrug-Resistant Organisms: Getti… (10.1093/ofid/ofab531) | Abstract ORCID License | 102.13 | 22 |
| 28 | 401A Phase 1 Study of the Safety, Tolerability, and Pharmaco… (10.1093/ofid/ofu052.267) | Abstract References ORCID License | 100.00 | 9 |
| 29 | LB-1Treatment with Oral ALS-008176, a Nucleoside Analog, Rap… (10.1093/ofid/ofu083.01) | Abstract References ORCID License | 100.00 | 9 |
| 30 | Multiple Ascending Dose Safety, Tolerability, and Pharmacoki… (10.1093/ofid/ofx163.662) | Abstract References ORCID License | 100.00 | 9 |
| 31 | Safety and Tolerability of 514G3, a True Human Anti-Protein… (10.1093/ofid/ofw172.1057) | Abstract References ORCID | 99.17 | 20 |
| 32 | Safety and Tolerability of Long Term Use of Tedizolid for Tr… (10.1093/ofid/ofw172.440) | Abstract References ORCID | 99.17 | 20 |
| 33 | Influence of Antibiotics on the Detection of Bacteria by Cul… (10.1093/ofid/ofx014) | ORCID License | 98.89 | 94 |
| 34 | Histoplasmosis, An Underdiagnosed Disease Affecting People L… (10.1093/ofid/ofz073) | Abstract ORCID | 98.66 | 93 |
| 35 | Host Characteristics and Bacterial Traits Predict Experiment… (10.1093/ofid/ofv083) | ORCID License | 97.71 | 89 |
| 36 | Trends in Hospitalizations Related to Invasive Aspergillosis… (10.1093/ofid/ofw268) | ORCID License | 97.47 | 88 |
| 37 | Risk Factors for Community-Associated Clostridium difficile… (10.1093/ofid/ofx171) | ORCID License | 96.72 | 85 |
| 38 | Plasma Proinflammatory Cytokines Are Markers of Disease Seve… (10.1093/ofid/ofz257) | ORCID License | 96.21 | 83 |
| 39 | Age-Related Differences in Hospitalization Rates, Clinical P… (10.1093/ofid/ofz225) | ORCID License | 95.69 | 81 |
| 40 | CHIKUNGUNYA: A Mortality Report (10.1093/ofid/ofx163.1348) | Abstract References ORCID License | 95.42 | 8 |
| 41 | A Phase 2a Study to Evaluate the Safety of MEDI8852 in Outpa… (10.1093/ofid/ofx163.1352) | Abstract References ORCID License | 95.42 | 8 |
| 42 | Safety and Pharmacokinetics (PK) in Humans of Intravenous ET… (10.1093/ofid/ofx163.1366) | Abstract References ORCID License | 95.42 | 8 |
| 43 | Direct Detection and Quantification of Bacterial Cell-free D… (10.1093/ofid/ofx163.1613) | Abstract References ORCID License | 95.42 | 8 |
| 44 | T-Cell Immunity Panel Measures CMV-Specific CD4 and CD8 T-Ce… (10.1093/ofid/ofx163.1620) | Abstract References ORCID License | 95.42 | 8 |
| 45 | Rapid Detection of Invasive Mycobacterium chimaera Infection… (10.1093/ofid/ofx163.315) | Abstract References ORCID License | 95.42 | 8 |
| 46 | Seroprevalence of Measles, Mumps, Rubella and Varicella Anti… (10.1093/ofid/ofv006) | ORCID License | 95.15 | 79 |
| 47 | Bezlotoxumab Alone and With Actoxumab for Prevention of Recu… (10.1093/ofid/ofv131.06) | Abstract References ORCID | 94.15 | 17 |
| 48 | Prospective Assessment of Donor Eligibility for Fecal Microb… (10.1093/ofid/ofv133.678) | Abstract References ORCID | 94.15 | 17 |
| 49 | Safety and Efficacy of Fecal Microbiota Transplantation for… (10.1093/ofid/ofw172.1668) | Abstract References ORCID | 94.15 | 17 |
| 50 | The Pandemic H30 Subclone of Sequence Type 131 (ST131) as th… (10.1093/ofid/ofx089) | ORCID License | 93.75 | 74 |